RenovoRx Executives to Present at Canaccord Genuity Forum
Company leadership will discuss recent financial results and commercial operations on November 11, 2026.
Updated on Oct. 28, 2026 in Healthcare
Live Poll
Are you planning to invest in medical technology companies based on their clinical trial progress?
RenovoRx, a Nasdaq-listed medical firm based in Mountain View, will present at the Canaccord Genuity MedTech Diagnostics and Digital Health & Services Forum on November 11, 2026. Executives plan to review financial performance and provide updates on commercial execution.
Why it matters
This presentation allows the company to detail its ongoing commercial strategy for the FDA-cleared RenovoCath device and provide progress updates on its clinical pipeline. Stakeholders will gain insight into how the company is translating its drug-delivery technology into operational growth.
RenovoRx reported $909,000 in revenue for the second quarter of 2026, following $1.1 million in RenovoCath sales generated throughout 2025. The company has achieved full enrollment in its TIGeR-PaC clinical trial as of August 2026.
The players
RenovoRx
A publicly traded medical device company headquartered in Mountain View that focuses on developing innovative drug-delivery therapies.
Canaccord Genuity
A global financial services firm that hosts industry forums to connect emerging medical technology companies with investors.
The details
The company focuses on its TAMP platform, which utilizes the FDA-cleared RenovoCath device to deliver therapeutic agents directly across arterial walls to tumor sites. The upcoming presentation will highlight how this targeted delivery technology is being commercialized and deployed within the medical sector.
Timeline
2025: RenovoRx generated $1.1 million in RenovoCath sales.
Q2 2026: The company reported $909,000 in quarterly revenue.
August 2026: RenovoRx achieved full enrollment in the TIGeR-PaC trial.
November 11, 2026: RenovoRx executives present at the Canaccord Genuity Forum.
First half 2027: Expected completion of the TIGeR-PaC clinical trial.
Market Landscape
The presentation serves as an update on the progress of the TIGeR-PaC clinical trial, which remains the company's primary focus for future therapy validation. This progress helps position RenovoRx against other specialized firms competing in the targeted drug-delivery and medical diagnostics market.
The company's commercial execution impacts investors monitoring the potential market adoption of the RenovoCath device. Patients and healthcare providers may see broader availability of targeted therapy options as the company advances its clinical trials toward data release.
The takeaway
The firm is balancing active commercial sales of its current device with the intensive requirements of an ongoing clinical trial. Shareholders are closely watching the 2027 project milestones as key indicators of the company's long-term commercial potential.
What happens next
RenovoRx anticipates finishing the TIGeR-PaC clinical trial in the first half of 2027, followed by an expected topline data readout in the second half of 2027.
Further reading
For more information on sector trends, visit the Mountain View Healthcare page.
More information
View the webcast replay and investor event calendar for additional company documentation.
Source note: This article includes information reported by The Manila times.
Live Poll
Are you planning to invest in medical technology companies based on their clinical trial progress?
